Several successful pharmacological projects were presented at the International Forum on Technological Development “Technoprom-2024” by Maxim Korolev, Director of the Research Institute of Clinical and Experimental Lymphology (NIIKEL) of the branch of the Federal Research Center “Institute of Cytology and Genetics SB RAS” (ICiG SB RAS), Doctor of Medical Sciences, the SB RAS publication “Science in Siberia” reports on September 3 with reference to the press service of the FRC ICG SB RAS.
At the plenary session “Import substitution in healthcare” Maxim Korolev spoke about several drugs developed with NIIKEL’s participation. For example, for the treatment of patients with ankylosing spondylitis (radiation axial spondyloarthritis) with the industrial partnership of the Russian National Medical Research Institute named after him NI Pirogov and the biotechnology company BIOCAD developed the drug seniprutug.
Seniprutug was registered by the Ministry of Health of the Russian Federation in April 2024 and will be available for providing specialized and high-tech medical care within the framework of the compulsory medical insurance program. At NIIKEL, which is participating in the third phase of clinical trials of the drug, the drug will soon begin to be introduced into clinical practice.
The pharmacological project to develop a prototype drug for ankylosing spondylitis based on RNA aptamers has every chance of successful completion. The drug is being developed jointly by NIIKEL and the Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences and is currently in the preclinical research phase.
Another project is the creation of an antibacterial peptidomimetic for the treatment of infectious diseases caused by antibiotic-resistant pathogens. This drug can be used, for example, as part of a gel or in endoprostheses, together with bone cement granules.
The ophthalmology project is developing the use of immobilized hyaluronidase enzyme for the treatment of corneal lesions. The development is already at the stage of preclinical testing, which is being conducted at the Novosibirsk Regional Clinical Hospital.
Maxim Korolev concluded his message: “I would like to note that all conditions for successful pharmaceutical development have been created in the Novosibirsk region. The region has all the necessary institutions for producing molecules and conducting research, including clinics.”.
Source: Rossa Primavera
I am Michael Melvin, an experienced news writer with a passion for uncovering stories and bringing them to the public. I have been working in the news industry for over five years now, and my work has been published on multiple websites. As an author at 24 News Reporters, I cover world section of current events stories that are both informative and captivating to read.